| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 158.62 | 27.2% | 32.7% |
| Total Income | 161.26 | 28.4% | 34.0% |
| Expenditure | 169.16 | 21.6% | 24.4% |
| PBT | -7.90 | 49.6% | 49.6% |
| Net Profit | -7.75 | 50.6% | 51.8% |
| OPM | 5.77% | 4.25pp | 1.15pp |
| NPM | -4.80% | 7.69pp | 8.56pp |
| EPS | 3.48 | 50.6% | 57.6% |
Astec Q4 FY26 Income up 34% to ₹161.3 Cr; EBITDA up 87% to ₹11.8 Cr
27 Apr 2026 · 27 Apr, 8:22 pm
Summary
Astec LifeSciences Limited announced its financial results for the fourth quarter and full year ended March 31, 2026, demonstrating significant improvements. For Q4 FY26, consolidated total income grew by 34.0% year-on-year to ₹161.3 crore, largely driven by enhanced volumes across its Enterprise and Contract Manufacturing segments. The quarter also saw an 86.9% increase in consolidated EBITDA to ₹11.8 crore, with a considerable reduction in loss after tax to ₹7.7 crore. For the full fiscal year, total income rose 17.1% to ₹453.2 crore, and the company achieved an EBITDA breakeven of ₹0.5 crore, showcasing a strong recovery from the previous fiscal year's loss position. Chairperson Mr. Vishal Sharma attributed this performance to improved volumes in both Enterprise and CDMO segments, which also drove significant margin expansion.
Key Highlights
- 1
Astec LifeSciences Limited reported a consolidated total income of ₹161.3 crore in Q4 FY26, marking a robust 34.0% increase year-on-year from ₹120.3 crore in Q4 FY25.
- 2
The company's consolidated EBITDA surged by 86.9% to ₹11.8 crore in Q4 FY26, compared to ₹6.3 crore in Q4 FY25.
- 3
Loss after tax for Q4 FY26 significantly improved to ₹7.7 crore, reducing from a loss of ₹16.1 crore in the corresponding quarter of the previous year.
- 4
For the full financial year FY26, consolidated total income reached ₹453.2 crore, growing 17.1% from ₹386.9 crore in FY25.
- 5
Astec achieved an EBITDA breakeven of ₹0.5 crore for FY26, a notable turnaround from an EBITDA loss of ₹60.6 crore in FY25.
- 6
The full-year loss after tax for FY26 narrowed to ₹80.9 crore, improving from a loss of ₹134.7 crore reported in FY25.
- 7
Q4 FY26 revenue growth was primarily fueled by improved volumes in the Enterprise segment (up 37.1% to ₹69.2 crore) and the Contract Manufacturing & New Products segment (up 29.5% to ₹89.4 crore).
Management Comments
Mr. Vishal Sharma
In Q4FY26, Astec delivered strong revenue growth of 34% y-o-y primarily on the back of improved volumes in both the categories, i.e. Enterprise and Contract Manufacturing segment. Revenue increased sequentially as well by 29% over Q3FY26, primarily driven by Enterprise Volumes. Improved volumes in the Enterprise and CDMO segments drove a significant margin expansion, leading to an increase in EBITDA to ₹11.8 crore in Q4FY26 from ₹6.3 crore in Q4FY25, an 87% y- o-y growth.
Informational and educational content only. Not investment advice.